Clinical Trial Results:
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of
VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone
(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and
Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center
B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Summary
|
|
EudraCT number |
2009-012280-34 |
Trial protocol |
BE PT CZ DE FR ES IT IE |
Global completion date |
10 Jun 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Jun 2016
|
First version publication date |
24 Jun 2016
|
Other versions |
|
Summary report(s) |
26866138LYM2034 (2009-012280-34)_CT.gov results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.